May I also add that it does not take the normal length of time for sd-rxRNA to produce results on scar reduction to satisfy the FDA. Therefore, we can expect results on Phase 2 of RXI-109 for scar reduction within 2 months. Then it will be onto Phase 3 with results in Q1 or Q2 in 2015.
I may be wrong. I do not expect doctors in the EU will jump on RXI-109 en mass before the FDA approves it. Additionally, I think it may take a bit longer than 3 months to ramp up the sale of it in Europe. I stand to be corrected, especially if somebody can provide some facts to prove that I am too optimistic.
On a separate issue about how long RXII must consistently stay above $4 before Nasdaq will up list it. I remember I read it some official document before indicating that the time frame is 30 trading days. I wish Tamara can be more specific in stating the official Nasdaq rule on this.